Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
R Alvarez, M Musteanu, E Garcia-Garcia… - British journal of …, 2013 - nature.com
Background: Nab-paclitaxel and gemcitabine have demonstrated a survival benefit over
gemcitabine alone in advanced pancreatic cancer (PDA). This study aimed to investigate the …
gemcitabine alone in advanced pancreatic cancer (PDA). This study aimed to investigate the …
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
HA Burris 3rd, MJ Moore, J Andersen… - Journal of clinical …, 1997 - ascopubs.org
PURPOSE Most patients with advanced pancreas cancer experience pain and must limit
their daily activities because of tumor-related symptoms. To date, no treatment has had a …
their daily activities because of tumor-related symptoms. To date, no treatment has had a …
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
M Tempero, W Plunkett, V Ruiz van Haperen… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: To conduct a randomized phase II trial of dose-intense gemcitabine using a
standard 30-minute infusion or the fixed dose rate (FDR) infusion (10 mg/m2/min) in patients …
standard 30-minute infusion or the fixed dose rate (FDR) infusion (10 mg/m2/min) in patients …
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
KKY Cham, JHE Baker, KS Takhar, JA Flexman… - British journal of …, 2010 - nature.com
Background: The current standard of care for pancreatic cancer is weekly gemcitabine
administered for 3 of 4 weeks with a 1-week break between treatment cycles. Maximum …
administered for 3 of 4 weeks with a 1-week break between treatment cycles. Maximum …
Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil
H Burris, AM Storniolo - European journal of cancer, 1997 - Elsevier
An early study with gemcitabine in pancreas cancer indicated greater relief of disease-
related symptoms than expected from the objective tumour response rate. A novel design …
related symptoms than expected from the objective tumour response rate. A novel design …
High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer.
HF Gao, K Wang, ZQ Meng, Z Chen, JH Lin… - Hepato …, 2013 - europepmc.org
Results There were no severe complications or adverse events related to HIFU therapy in
any of the patients treated. Pain relief was achieved in 79.5% of patients. Median TTP was …
any of the patients treated. Pain relief was achieved in 79.5% of patients. Median TTP was …